A Clinical Study of the Anti‑cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

Trial status:Recruiting
Trial ID:
BNT323-01
NCT ID:
NCT06340568
EudraCT ID:
N/A
EU Trial (CTIS) Number:
2023-507525-42-00
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech SE
Recruiting

Trial Details

The goal of this clinical study is to assess the efficacy of BNT323/DB-1303 compared with investigator's choice of chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the endometrial cancer population with prior immune checkpoint inhibitor (ICI) treatment.

Medical Condition
  • Endometrial Cancer
    • Trial Drug
  • BNT323/DB-1303
    • See more
  • Doxorubicin
  • Paclitaxel
    • Phase
    Phase 3
    Type
    Interventional
    Estimated Enrolment
    504
    Estimated Trial Date
    Jun 2025 - Mar 2028

    Trial Participant Requirements

    Age
    18+ years
    Sex
    Female
    Healthy Volunteers
    No
    Inclusion and Exclusion Criteria
    Inclusion criteria
    • Are female adults (defined as ≥18 years of age or acceptable age according to local regulations at the time of voluntarily giving informed consent).
    • Have histologically confirmed endometrial cancer that:
      • Is recurrent,
      • Has a HER2 IHC score of 1+, 2+, or 3+ as determined by central laboratory testing for HER2 protein expression, and
      • Is not defined as a true sarcoma (i.e., leiomyosarcoma or endometrial stromal sarcoma). Note: Uterine carcinosarcoma is allowed.
    • Have measurable disease defined by RECIST 1.1.
    • Have Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1 or 2.
    • Have had at least one prior line of platinum-based therapy (in any setting). Up to three lines of prior therapy are allowed. Prior hormonal therapy and radiation are allowed and do not count as prior lines of therapy. Platinum-based chemotherapy and ICI may have been given together or in separate lines of therapy.
    • Have a life expectancy of ≥12 weeks at screening.
    Exclusion criteria
    • Ineligible for all options in the investigator's choice of chemotherapy arm. Participants with contraindications to paclitaxel and doxorubicin treatment, per local prescribing information and institutional guidelines, cannot be enrolled to the study.
    • Have a history of small bowel obstruction requiring hospitalization within the past 3 months prior to randomization.
    • Have an uncontrolled intercurrent illness that would limit compliance with study requirement or substantially increase risk of incurring adverse events (AEs).
    • Have clinically uncontrolled pleural effusion, ascites or pericardial effusion requiring drainage, peritoneal shunt, or cell-free concentrated ascites reinfusion therapy within 2 weeks prior to randomization.
    • Have a history of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids, have current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at screening.
    • Participants with prior use of immunosuppressive medication within 14 days prior to first dose of study treatment, except for intranasal and inhaled corticosteroids or systemic corticosteroids at doses of less than 10 mg/day of prednisone or equivalent, and topical corticosteroids. Participants receiving corticosteroids may continue if the dose is stable upon giving informed consent.
    • Have a lung-specific intercurrent clinically significant illness including, but not limited to, any underlying pulmonary disorder (e.g., pulmonary emboli within 3 months prior to study randomization, severe asthma, severe chronic obstructive pulmonary disorder, restrictive lung disease, pulmonary fibrosis, radiation pneumonitis, significant pleural effusion etc.), and any autoimmune, connective tissue or inflammatory disorder with pulmonary involvement (i.e., rheumatoid arthritis, Sjogren's syndrome, sarcoidosis etc.), and/or prior pneumonectomy (complete).
    • Have uncontrolled infection requiring systemic antibiotics, antivirals, or antifungals within 2 weeks prior to randomization.
    • Have unresolved toxicities from previous anti-cancer therapy, defined as toxicities (other than alopecia) not yet resolved to Grade ≤1 or baseline.
    • Are pregnant or breastfeeding or are planning pregnancy during the study or within 7 months after the last dose of study treatment.
    • Have a history of allergies, hypersensitivities, or intolerance to the study treatments (investigational medicinal products and auxiliary medicinal product) including any excipients thereof or to other monoclonal antibodies.
    • Had prior treatment with topoisomerase I inhibitors, including ADCs with exatecans.
    • Have left ventricular ejection fraction (LVEF) \<55% by either echocardiography (ECHO) or multiple-gated acquisition (MUGA) within 28 days before randomization. This includes participants with tissue doppler E/e' ratio \>15.

      • NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

    Trial Locations

    Location
    Status
    Location
    Sunshine Hospital
    Saint Albans, Australia, 3021
    Status
    Recruiting
    Location
    Cancer Hospital of Shantou University Medical College
    Shantou, Guangdong, China, 515031
    Status
    Recruiting
    Location
    Hubei Cancer Hospital
    Wuhan, Hubei, China, 430079
    Status
    Recruiting
    Location
    Jiangxi Maternal and Child Health Hospital
    Nanchang, Jiangxi, China, 330006
    Status
    Recruiting
    Location
    Fudan University Shanghai Cancer Center
    Shanghai, China, 200032
    Status
    Recruiting
    Location
    China Medical University Hospital
    Taichung, Taiwan, Province of China, 404
    Status
    Recruiting
    Go to page